Nicholas A.J. Botwood

Executive

Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Inc

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 1 buy · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (1 ops.)

€95k

▼ Sales (2 ops.)

—

Latest filing published 12 Jun 2026 for Syndax Pharmaceuticals Inc. Read the official filing

Filing timeline

BuySale

Nicholas A.J. Botwood

Insider track record

Disclosed buys

Disclosed sells

Signal history

No signal scores available.

Closed purchases

Market purchases

Not enough history yet: 1 closed purchase, at least 2 are needed.

Purchases by company

Syndax Pharmaceuticals Inc 1 purchase · last 19 May 2025

Since each purchase

Syndax Pharmaceuticals Inc
Filed 19 May 2025 · 517 days ago · €95k
+90.4%
Entry US$10.57 · Close at T+365 US$20.13

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Nicholas A.J. Botwood: trading record in brief

Nicholas A.J. Botwood is a declared insider of Syndax Pharmaceuticals Inc, with filings sourced from SEC (Form 4). Over a trading history stretching from 16 May 2025 to 12 June 2026, the count stands at 6 filings.

In open-market terms, that means 1 purchase worth €95k on one side and 2 sales on the other. The totals do not cover 2 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant and 2 option exercises. In 2026 alone, the filings show no purchases and 2 sales.

On 12 June 2026 came the latest disclosure, an option exercise in Syndax Pharmaceuticals Inc. The most recent open-market purchase was published on 19 May 2025, 517 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.